Peptide Library

Human study PLS-00139

Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure.primary · Hepatobiliary & pancreatic diseases international : HBPD INT · 2022-08-19 · PMID 36041971 · DOI

Design and participants

Design
Other design
Population
Patients with acute-on-chronic hepatitis B liver failure (115; early, mid and advanced stage subgroups), pre-liver failure (80), chronic hepatitis B (86), and healthy controls (36).
Conditions
Acute-on-chronic hepatitis B liver failure, Chronic hepatitis B
Setting
Department of Hepatology, Qilu Hospital of Shandong University (China)
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Tβ4 promoter methylation in blood mononuclear cells may be an important early marker for predicting incidence and prognosis in acute-on-chronic hepatitis B liver failure, outperforming MELD score in earlier stages.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: Patients had hepatitis B liver disease and were not given thymosin β4; endogenous gene methylation was measured instead.
    • abstract only: Only the PubMed abstract is available, with no full methods, statistics or funding information.
    • inappropriate endpoint: The study measures endogenous Tβ4 methylation as a prognostic marker. It gives no information on the effect or safety of administered Tβ4.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 36041971, abstract (Conclusions, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 36041971, abstract (Methods, sentences 1-4) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 36041971, abstract (Methods, sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 36041971, abstract (Methods, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).